China Biopsy Device Market will be US$ 1,059.41 Million by 2032

China Biopsy Device Market Size

China's Biopsy Device Market is expected to be almost US$1,059.41 million by 2032, compared to US$574.31 million in 2023. Renub Research stated that the industry is foreseen to increase at a CAGR of 7.04% from 2024 to 2032.

A biopsy is a process to terminate a portion of tissue or a sample of cells from the body to be tried in a laboratory. People may undergo a biopsy if they are experiencing certain signs and symptoms or if the health care provider has identified an area of concern. A biopsy can determine whether an individual has cancer or another condition. Imaging tests, such as CT scans or MRIs, help detect masses or irregular tissue, but they alone can't tell the difference between cancerous cells and cells that aren't cancerous. For most cancers, the only way to make a diagnosis is to conduct a biopsy to gather cells for a more intimate assessment.

Request a free sample copy of the report: https://www.renub.com/china-biopsy-market-p.php

Biopsy devices are essential tools in diagnosing and treating cancer, enabling the extraction of tissue samples for examination and pathology. The demand for these devices in China is fueled by the increasing incidence of cancer, which has become a significant public health concern. According to the World Health Organization, cancer rates in China are among the highest globally, with lung, breast, and colorectal cancers being particularly prevalent.

Several key factors contribute to the growth of the biopsy device market in China. The country’s expanding healthcare infrastructure and increasing investment in medical technology are crucial. The Chinese government has prioritized healthcare in its national development agenda, leading to significant improvements in hospital facilities and the availability of advanced medical equipment.

Technological advancements are another driving force. Innovations in imaging techniques, such as ultrasound-guided, MRI-guided, and CT-guided biopsies, have improved the accuracy and efficiency of biopsy procedures. Additionally, the development of minimally invasive biopsy devices has reduced patient discomfort and recovery times, making these procedures more appealing to patients and healthcare providers.

The market also benefits from the growing adoption of personalized medicine and precision oncology. As treatments become more tailored to individual patients, the demand for accurate and timely diagnostic tools, including biopsy devices, increases. This trend is supported by advances in molecular diagnostics and biomarker discovery, which require high-quality tissue samples for analysis.

Local and international companies actively compete in the Chinese biopsy device market, driving innovation and accessibility. Major global players such as Medtronic, BD (Becton, Dickinson, and Company), and Hologic have established a strong presence, while local manufacturers are also emerging, contributing to market growth through cost-effective and innovative solutions.

Regulatory support from the Chinese government, including streamlined approval processes for medical devices, further accelerates market expansion. However, challenges such as the need for skilled healthcare professionals and regional disparities in healthcare access remain.

China Biopsy Device Industry News

The China biopsy device market is segmented into various companies, such as Bio-Rad Laboratories, Exact Sciences (Genomic Health), Becton, Dickinson and Company, Roche Diagnostics, Thermo Fisher Scientific Inc., Qiagen, Biocept, Quest Diagnostics Inc., and NeoGenomics Laboratories.

In October 2023 - LUMINELLE announced its decision to expand its global footprint by receiving a patent for its LUMINELLE Bx (Biopsy) System from the China National Intellectual Property Administration.

In September 2023 - Baird Medical Investment Holdings Limited reported that Jiangsu Medical Products Administration, the pharmaceuticals regulatory authority for Jiangsu Province in China, has approved its Single-Use Sterile Biopsy Needle ("SSBN") through its subsidiary Nanjing Changcheng Medical Equipment Co., Ltd. The device, approved on August 30, 2023, and has registration number 20232141234, is used for biopsies of tumors in superficial tissues close to the skin's surface, such as the thyroid, lymph nodes, and breasts.

In July 2023 - The cfDNA liver cancer detection test from Helio Genomics' sister company, Laboratory for Advanced Medicine and Health Group (LAMH), received approval from China's National Medical Products Administration (NMPA). It is stated to be a first in the field of blood-based cancer detection—the first liquid biopsy test authorized by NMPA for liver cancer.

Products – Market is broken up into 4 viewpoints:

1. Needle Based Biopsy Devices

2. Biopsy Forceps

3. Localization Wire

4. Others Products

Imaging Technology – Market is broken up into 5 viewpoints:

1. CT scan

2. Stereotactic Guided

3. Ultrasound Guided

4. MRI Guided

5. Others

End-User – Market is broken up into 3 viewpoints:

1. Hospital and Clinics

2. Diagnostics Laboratories

3. Other

All companies have been covered from 3 viewpoints:

• Overview

• Recent Development

• Revenue

Company Analysis:

1. Bio-Rad Laboratories

2. Exact Sciences (Genomic Health)

3. Becton, Dickinson and Company

4. Roche Diagnostics

5. Thermo Fisher Scientific Inc.

6. Qiagen

7. Biocept

8. Quest Diagnostics Inc.

9. NeoGenomics Laboratories

Related Reports:

Contact Lenses Market

Global Self-Monitoring Blood Glucose Device Market

Cardiac Holter Monitor Market

About the Company:

Renub Research is a Market Research and Information Analysis company with more than 15 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 9000 syndicated reports and worked on more than 750 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.